Coverage and Fidelity of the Xpert MTB/RIF™ Implementation in a High-burden Area for Pulmonary Tuberculosis in Colombia

Overview

Journal Biomedica

Specialty General Medicine

Date 2020 Dec 4

PMID 33275342

Citations 2

Authors

Freddy Agredo

Lyda Osorio

Affiliations

Soon will be listed here.

Abstract

Introduction: The Xpert MTB/RIF™ is a rapid molecular test that diagnoses tuberculosis and rifampin resistance. Since 2010, it is recommended by the World Health Organization (WHO) and although it was introduced in Colombia since 2012, the results of its implementation are unknown. Objective: To describe the coverage and fidelity in the implementation of the Xpert MTB/RIF™ in patients with pulmonary tuberculosis in a city with a high burden for the disease in Colombia. Materials and methods: We conducted a retrospective, descriptive study of cases from a tuberculosis program in Cali between 2013 and 2019. We estimated the coverage as the total number of tests used compared to the cases registered in the program and the fidelity based on international Xpert MTB/RIF™ implementation protocols. We performed a multivariate analysis of multiple correspondences between the test and the sociodemographic variables. Results: We included 6,328 patients with pulmonary tuberculosis of whom 181 were drugresistant. The Xpert MTB/RIF™ coverage was 10,3% (n=655) with an annual variation between 0.2% and 23%. Loyalty among the highest risk groups of MDR-TB was 46.8%. The use of the test was related to being an Afro-Colombian man between 41 and 60 years of age. Conclusions: The coverage of the Xpert MTB/RIF in Cali is low and its use does not follow the recommended prioritization for its implementation. Implementation strategies are required for its proper use to contribute to the goal of ending tuberculosis.

Citing Articles

Treatment for multidrug-resistant tuberculosis: A comparative analysis of programmatic outcome indicators between Buenaventura and other municipalities of Valle del Cauca, Colombia.

Hoyos D, Meza R, Forero L, Moreira C, Ferro B, Pacheco R Biomedica. 2024; 44(3):402-415.

PMID: 39241242 PMC: 11463525. DOI: 10.7705/biomedica.7204.

Effect of Big Data Analysis-Based Remote Management Combined with Yangyin Runfei Decoction on Coagulation Function, Pulmonary Function, and Quality of Life of Pulmonary Tuberculosis Patients.

Jin H Comput Intell Neurosci. 2022; 2022:1708133.

PMID: 35510056 PMC: 9061019. DOI: 10.1155/2022/1708133.

References

Caminero Luna J . Update on the diagnosis and treatment of pulmonary tuberculosis. Rev Clin Esp (Barc). 2015; 216(2):76-84. DOI: 10.1016/j.rce.2015.09.005. View

Sikhondze W, Dlamini T, Khumalo D, Maphalala G, Dlamini S, Zikalala T . Countrywide roll-out of Xpert(®) MTB/RIF in Swaziland: the first three years of implementation. Public Health Action. 2015; 5(2):140-6. PMC: 4487476. DOI: 10.5588/pha.15.0001. View

Choi H, Miele K, Dowdy D, Shah M . Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States. Int J Tuberc Lung Dis. 2013; 17(10):1328-35. PMC: 3891798. DOI: 10.5588/ijtld.13.0095. View

Hanrahan C, Haguma P, Ochom E, Kinera I, Cobelens F, Cattamanchi A . Implementation of Xpert MTB/RIF in Uganda: Missed Opportunities to Improve Diagnosis of Tuberculosis. Open Forum Infect Dis. 2016; 3(2):ofw068. PMC: 4866550. DOI: 10.1093/ofid/ofw068. View

Eslava-Schmalbach J, Garzon-Orjuela N, Elias V, Reveiz L . [Incorporating health equity into implementation research: review of conceptual modelsIncorporação da igualdade em saúde na pesquisa de implementação: revisão de modelos conceituais]. Rev Panam Salud Publica. 2019; 41:e126. PMC: 6645188. DOI: 10.26633/RPSP.2017.126. View

Chakravorty S, Simmons A, Rowneki M, Parmar H, Cao Y, Ryan J . The New Xpert MTB/RIF Ultra: Improving Detection of and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing. mBio. 2017; 8(4). PMC: 5574709. DOI: 10.1128/mBio.00812-17. View

Breitenstein S, Gross D, Garvey C, Hill C, Fogg L, Resnick B . Implementation fidelity in community-based interventions. Res Nurs Health. 2010; 33(2):164-73. PMC: 3409469. DOI: 10.1002/nur.20373. View

Mishra B, Rockey S, Gupta S, Srinivasa H, Muralidharan S . Multi-drug-resistant tuberculosis: the experience of an urban tertiary care hospital in South India using automated BACTEC 460 TB. Trop Doct. 2011; 42(1):35-7. DOI: 10.1258/td.2011.110247. View

Lawn S, Mwaba P, Bates M, Piatek A, Alexander H, Marais B . Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis. 2013; 13(4):349-61. PMC: 4844338. DOI: 10.1016/S1473-3099(13)70008-2. View

10.

Ardizzoni E, Fajardo E, Saranchuk P, Casenghi M, Page A, Varaine F . Implementing the Xpert® MTB/RIF Diagnostic Test for Tuberculosis and Rifampicin Resistance: Outcomes and Lessons Learned in 18 Countries. PLoS One. 2015; 10(12):e0144656. PMC: 4682866. DOI: 10.1371/journal.pone.0144656. View

11.

Suarez-Obando F, Gomez-Restrepo C, BOGOTa S . Implementation science: from evidence to practice. Acta Med Colomb. 2019; 43(4):207-216. PMC: 6614059. View

12.

Cowan J, Michel C, Manhica I, Mutaquiha C, Monivo C, Saize D . Remote monitoring of Xpert® MTB/RIF testing in Mozambique: results of programmatic implementation of GxAlert. Int J Tuberc Lung Dis. 2016; 20(3):335-41. DOI: 10.5588/ijtld.15.0535. View

13.

Albert H, Nathavitharana R, Isaacs C, Pai M, Denkinger C, Boehme C . Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?. Eur Respir J. 2016; 48(2):516-25. PMC: 4967565. DOI: 10.1183/13993003.00543-2016. View

14.

Steingart K, Sohn H, Schiller I, Kloda L, Boehme C, Pai M . Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2013; (1):CD009593. PMC: 4470352. DOI: 10.1002/14651858.CD009593.pub2. View

15.

Scott L, Beylis N, Nicol M, Nkuna G, Molapo S, Berrie L . Diagnostic accuracy of Xpert MTB/RIF for extrapulmonary tuberculosis specimens: establishing a laboratory testing algorithm for South Africa. J Clin Microbiol. 2014; 52(6):1818-23. PMC: 4042800. DOI: 10.1128/JCM.03553-13. View

16.

Detjen A, DiNardo A, Leyden J, Steingart K, Menzies D, Schiller I . Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and meta-analysis. Lancet Respir Med. 2015; 3(6):451-61. PMC: 4756280. DOI: 10.1016/S2213-2600(15)00095-8. View

17.

Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A . Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2010; 38(2):65-76. PMC: 3068522. DOI: 10.1007/s10488-010-0319-7. View

18.

Rodriguez D, Verdonck K, Bissell K, Victoria J, Khogali M, Marin D . Monitoring delays in diagnosis of pulmonary tuberculosis in eight cities in Colombia. Rev Panam Salud Publica. 2016; 39(1):12-18. View

19.

Moreira C, Hernandez H, Arias N, Castano M, Ferro B, Jaramillos E . [Initial drug resistance as a threat for tuberculosis control: the case of Buenaventura, Colombia]. Biomedica. 2004; 24 Supp 1:73-9. View

20.

Rojas C, Villegas S, Pineros H, Chamorro E, Duran C, Hernandez E . [Clinical, epidemiological and microbiological characteristics of a cohort of pulmonary tuberculosis patients in Cali, Colombia]. Biomedica. 2011; 30(4):482-91. View